Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Meningococcal Vaccine
- Sponsor
- University of Florida
- Enrollment
- 1326
- Locations
- 6
- Primary Endpoint
- Vaccine uptake in adolescents and young adults
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
As part of an effort to increase MenB vaccine uptake among adolescents and young adults, study teams will conduct qualitative research to maximize the effectiveness of nationally recommended MenB educational materials. In this study, Study Teams will assess local barriers to MenB vaccination by conducting focus groups with parents, students, and health care professionals.
Detailed Description
Participants (parents of 16-23 year old teens and young adults, high school and college students 16-23 years old, and health care professionals for 16-23 year olds) will be asked to share their thoughts on the completeness of nationally recommended and publicly available MenB vaccine educational materials in addressing hesitations to receipt of the MenB vaccine. There is no risk in discussing reactions to educational materials. The biggest risk is disclosure of information provided in the study which will be reactions to health-promotion material.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must be able to provide informed consent or assent
Exclusion Criteria
- •Inability to provide informed consent or assent
Outcomes
Primary Outcomes
Vaccine uptake in adolescents and young adults
Time Frame: 12 months
Percentage receiving MenB vaccine
Knowledge about MenB vaccine efficacy, potential benefits, possible side effects
Time Frame: 12 months
Percent of parents and young adults with Men B knowledge
Secondary Outcomes
- Attitudes re: Meningococcal B vaccine(12 months)